# US 8,277,778 B2 · Vaccine adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,778 B2
- Document ID: US8277778B2
- Status: Granted
- Kind: B2
- Application number: 13/242,909
- Filed: 2011-09-23
- Published: 2012-01-19
- Granted: 2012-10-02
- Earliest claimed: 2005-04-25
- Assignees: Cadila Pharmaceuticals Ltd.
- Inventors: Bakulesh Mafatlal Khamar; Rajiv Indravadan Modi; Indravadan Ambalal Modi; Prasanta Kumar Ghosh; Nirav Desai
- Web page: https://patentgrep.com/patent/US8277778B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K 2039/55594: {from bacteria}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.

## Claims

### Claim 1

A method for generating an immune response against an antigen by administration of a pharmaceutical composition comprising said antigen and Mycobacterium w and/or constituents thereof as an adjuvant.

### Claim 2 (depends on 1)

The method as claimed in claim 1 wherein the antigen(s) is a cell, a virus, a bacterium, a fungus, a parasite, a constituent thereof or a combination thereof.

### Claim 3 (depends on 1)

The method as claimed in claim 1 wherein the antigen is selected from the group consisting of one or more peptides, one or more polypeptides, one or more cells, one or more cell extracts, one or more polysaccharides, one or more polysaccharide conjugates, one or more lipids, one or more glycolipids, one or more carbohydrates, one or more proteins, one or more viruses, one or more viral extracts, and one or more nucleic acid-based antigen encoded in nucleic acids.

### Claim 4 (depends on 1)

The method as claimed in claim 1 wherein the antigen is an allergen.

### Claim 5 (depends on 1)

The method as claimed in claim 1 wherein the antigen is a tumor associated antigen.

### Claim 6 (depends on 1)

The method as claimed in claim 1 wherein the antigen is a tumor specific antigen.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the immune response generated is a humoral immune response.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the immune response generated is a cell mediated immune response.

### Claim 9 (depends on 1)

The method as claimed in claim 1 wherein the administration of said Mycobacterium w and/or constituents thereof to a mammal induces or enhances immunogenicity of said antigen(s).

### Claim 10 (depends on 1)

The method as claimed in claim 1 is used for the treatment of a disease.

### Claim 11 (depends on 10)

The method as claimed in claim 10 wherein the treatment comprises generating immune response against a disease specific antigen.

### Claim 12 (depends on 1)

The method as claimed in claim 1 wherein the administration of said Mycobacterium w and/or constituents thereof induces or enhances immunogenicity of antigen(s) resulting in decreased morbidity & mortality associated with a disease.

### Claim 13 (depends on 1)

The method as claimed in claim 1 wherein administration of said Mycobacterium w and/or constituents thereof when combined with another therapy in a diseased mammal induces or enhances immunogenicity of antigen(s) and results in decreased morbidity & mortality associated with disease.

### Claim 14 (depends on 1)

The method of claim 1 wherein said pharmaceutical composition is administered by a parenteral route.

### Claim 15 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition is administered by intramuscular, subcutaneous, or intradermal route.
